Short Summary
The plaintiff filed a suit seeking permanent injunction against the defendants for infringing its suit patents. The court examined the composition of the impugned products and found that they used exactly the same salt compositions as the plaintiffs' patented formulations. Consequently, the court granted an ex parte ad-interim injunction.
Detailed Summary
In the high-stakes world of pharmaceutical research, your unique formulation is your fortress. When a competitor breaches those walls by using the exact same building blocks, the law provides a swift shield. This case demonstrates exactly how that shield works when a competitor attempts to replicate a patented formula down to its chemical core.
Celagenex
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Delhi High Court - Orders. Understanding the court's reasoning in Celagenex Research India Pvt Ltd vs Pharmak & Anr. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Schneider Electric It CorporationvsAssistant Controller Of Patents And Designs
Schneider Electric It Corporation appealed an order by the Assistant Controller of Patents and Designs which rejected the grant of a patent application (No. 6134/DELNP/2015). The rejection was based on the alleged lack of inventive constructional features and failure to meet novelty and inventive step criteria. The court issued notice and directed both parties to file written submissions.
Bigtec Private LimitedvsThe Assistant Controller of Patents and Designs
Bigtec Private Limited appealed against the Assistant Controller's order declining the grant of patent for Indian Patent Application No. 314/CHE/2009, concluding that the claims lacked inventive step. The court set aside the impugned order due to non-consideration of appellant's contentions regarding prior art and remanded the matter for re-consideration by a different officer.
F Hoffmann-La Roche LtdvsDrugs Controller General Of India
The plaintiffs, innovators of biological cancer drugs 'bevacizumab' (AVASTIN) and 'trastuzumab' (HERCEPTIN), filed suits against the Drugs Controller General of India and associated defendants. The current judgment addresses applications seeking disclosure and production of documents related to the DCGI approvals granted to bio-similar versions of these drugs.
Pidilite Industries Ltd.vsS.M. Associates And Ors.
The Bombay High Court ruled in favor of Pidilite Industries Ltd., granting an injunction against the defendants for infringing its registered trademark 'M-Seal' and copyright. Despite the defense arguing that the assignment deed excluded the rights related to the stylized mark, the court found that the defendant was fully aware of the plaintiff's established rights. The judgment confirms the initial ad-interim order, restricting the infringement injunction to specific parts of the packaging.
Merck Sharp & Dohme Corp.vsTriveni Interchem Private Limited
The plaintiff, Merck Sharp & Dohme Corp., filed a suit alleging that the defendant, Triveni Interchem Private Limited, was selling and advertising various compositions of Sitagliptin without taking any license. The plaintiff holds a valid patent for Sitagliptin.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.